On October 22, 2026 Grid Therapeutics, a clinical-stage biotechnology company committed to developing better and safer human-derived therapeutic antibodies for cancer, reported that new data on its lead clinical asset, GT103, will be presented at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At the meeting, held October 23–27 in Madrid, Spain, the COMPACT consortium (EP PerMed) will present independent data showing that GT103’s tumor target, complement factor H (CFH), is a novel relevant tumor target in head and neck cancer, and that ex vivo GT103 reduces tumor cell proliferation while increasing tumor T-cells. This will be presented by Dr. Joey Martin (Centre de Recherche des Cordeliers/ Institut Curie, Paris, France).
Poster presentation title: Tumor-bound Factor H controls complement activation and is a potential therapeutic target in oral cavity and HPV-negative oropharyngeal squamous cell carcinoma (ESMO 2026; 1635eP).
GT103 is a tumor specific antibody that has been shown to kill tumor cells, inhibit metastasis, reduce the immunosuppressive environment, and drive anti-tumor immunity. "As we continue to explore and analyze pre-clinical data in different cancer cell types, the clinical development pathway options expand to multiple solid tumors," said Dr. Edward Patz, CEO of Grid. "In addition, we now have the confidence to move forward with additional assets from our computationally driven platform."
(Press release, Grid Therapeutics, OCT 22, 2026, View Source [SID1234673670])